Payment overview · 2025
General Payments
$372.06
19 reported records · 9 companies
Healthcare provider profile · identity verified
Stephen Wayne Harbin, MD
Allopathic & Osteopathic Physicians|Family Medicine · DECATUR, AL · NPI 1396813002
Verified facts
What the public records show
CMS Open Payments records show Stephen Wayne Harbin, MD received $372.06 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 36.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.36 | 36.9% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.84 | 16.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.16 | 8.6% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.88 | 8.6% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $29.91 | 8.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.37 | 7.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.66 | 5.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.45 | 4.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.43 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $372.06 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $115.47 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $95.13 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.84 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.16 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.16 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $31.88 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $29.91 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.37 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.37 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
35 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 723 | 176 |
| Atorvastatin Calcium | Atorvastatin Calcium | 690 | 194 |
| Amlodipine Besylate | Amlodipine Besylate | 668 | 169 |
| Metoprolol Succinate | Metoprolol Succinate | 436 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 380 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 358 | 98 |
| Omeprazole | Omeprazole | 303 | 99 |
| Metformin Hcl Er | Metformin Hcl | 289 | 82 |
| Lisinopril | Lisinopril | 272 | 76 |
| Telmisartan | Telmisartan | 267 | 57 |
| Celecoxib | Celecoxib | 259 | 85 |
| Famotidine | Famotidine | 239 | 83 |
| Losartan Potassium | Losartan Potassium | 239 | 69 |
| Montelukast Sodium | Montelukast Sodium | 228 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 223 | 44 |
| Prednisone | Prednisone | 202 | 148 |
| Valsartan | Valsartan | 196 | 50 |
| Irbesartan | Irbesartan | 193 | 46 |
| Carvedilol | Carvedilol | 187 | 46 |
| Furosemide | Furosemide | 187 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 187 | 51 |
| Trazodone Hcl | Trazodone Hcl | 187 | 52 |
| Eliquis | Apixaban | 178 | 41 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 172 | 45 |
| Buspirone Hcl | Buspirone Hcl | 170 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 54 |
| Allopurinol | Allopurinol | 160 | 43 |
| Ezetimibe | Ezetimibe | 158 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 79 |
| Donepezil Hcl | Donepezil Hcl | 145 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 139 | 35 |
| Simvastatin | Simvastatin | 138 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 36 |
| Levofloxacin | Levofloxacin | 132 | 111 |
| Potassium Chloride | Potassium Chloride | 131 | 46 |
| Sertraline Hcl | Sertraline Hcl | 129 | 38 |
| Gabapentin | Gabapentin | 128 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 31 |
| Glimepiride | Glimepiride | 103 | 26 |
| Mounjaro | Tirzepatide | 103 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 98 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 96 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 45 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 91 | 18 |
| Meloxicam | Meloxicam | 86 | 28 |
| Memantine Hcl | Memantine Hcl | 86 | 20 |
| Alprazolam | Alprazolam | 81 | 25 |
| Farxiga | Dapagliflozin Propanediol | 78 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 19 |
| Glipizide Er | Glipizide | 75 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 17 |
| Tramadol Hcl | Tramadol Hcl | 70 | 39 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 68 | 19 |
| Januvia | Sitagliptin Phosphate | 68 | 14 |
| Bupropion Xl | Bupropion Hcl | 67 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 66 | 18 |
| Spironolactone | Spironolactone | 66 | 19 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 63 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 51 |
| Ozempic | Semaglutide | 62 | 17 |
| Propranolol Hcl | Propranolol Hcl | 61 | 13 |
| Alendronate Sodium | Alendronate Sodium | 59 | 19 |
| Cefdinir | Cefdinir | 56 | 49 |
| Clonazepam | Clonazepam | 55 | 17 |
| Jardiance | Empagliflozin | 53 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 47 |
| Atenolol | Atenolol | 52 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 41 |
| Benazepril Hcl | Benazepril Hcl | 51 | 12 |
| Cefuroxime | Cefuroxime Axetil | 51 | 46 |
| Methocarbamol | Methocarbamol | 51 | 43 |
| Clobetasol Propionate | Clobetasol Propionate | 50 | 33 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 49 | 12 |
| Azithromycin | Azithromycin | 49 | 45 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 49 | 12 |
| Synthroid | Levothyroxine Sodium | 49 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 48 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 25 |
| Valacyclovir | Valacyclovir Hcl | 42 | 21 |
| Clonidine Hcl | Clonidine Hcl | 41 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 15 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 12 |
| Colchicine | Colchicine | 36 | 19 |
| Eszopiclone | Eszopiclone | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 21 |
| Nabumetone | Nabumetone | 35 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 35 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 33 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 25 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Estradiol | Estradiol | 30 | 11 |
| Metronidazole | Metronidazole | 30 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Mupirocin | Mupirocin | 29 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Rivastigmine | Rivastigmine | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | 13 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 19 |
| Trulicity | Dulaglutide | 25 | suppressed |
| Cephalexin | Cephalexin | 23 | 22 |
| Ramipril | Ramipril | 23 | suppressed |
| Metformin Hcl | Metformin Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Desonide | Desonide | 21 | 19 |
| Nystatin | Nystatin | 21 | 15 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 19 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Galantamine Hbr | Galantamine Hbr | 16 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Invokamet Xr | Canagliflozin/Metformin Hcl | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $372.06 · 19 records | Novo Nordisk Inc | Auvelity, FANAPT, Kerendia, Leqembi, NEXLETOL, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error